Plasek Joseph M, Amato Mary G, Salem Abigail, Foer Dinah, Lipsitz Stuart, Jackson Gretchen Purcell, Bates David W, Zhou Li
Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Drug Saf. 2025 Apr;48(4):363-374. doi: 10.1007/s40264-024-01501-w. Epub 2024 Dec 2.
Adverse drug events (ADEs) are understudied in the ambulatory care setting. We aim to estimate the prevalence and characteristics of ADEs in outpatient care using electronic health records (EHRs).
This cross-sectional study included EHR data for patients who had an outpatient encounter at an academic medical center from 1 October 2018 through 31 December 2019. We developed a stratified sampling strategy based on a comprehensive set of 994 ADE-related International Classification of Disease (ICD-10) codes to identify clinical encounters and notes likely to contain ADEs. Within each ICD-10 likelihood group, clinical notes were randomly sampled and annotated for present or possible ADE-drug relationships and severity. The overall estimated population prevalence of ADEs presenting in the outpatient setting was calculated. The generalizability of the findings was assessed by comparing ICD-10 code frequencies against a large commercial database.
The study included 3126 notes (unique patient encounters) from 2882 unique patients. Of these, 1383 patient encounters (44.2%) had a present or possible ADE documented (6308 mentions). Of the 6038 ADEs mentioned, 14.1% were hypersensitivity reactions, 1.1% were life-threatening, 22.4% were serious, and 60.4% were significant. Main causal agents included anti-infectives (19.3%), central nervous system agents (12.8%), and cardiovascular agents (11.5%). The overall prevalence of present ADEs mentioned in the clinical notes was estimated to be 1.97 per 100 patient encounters (or 2.52 per 100 patient encounters when possible ADEs are included).
This study identified the overall population prevalence per encounter of ADEs in the outpatient population by leveraging ICD-10 codes and investigating ADEs documented in clinical notes. Understanding the ADE characteristics in a large corpus of outpatient documentation advances pharmacovigilance knowledge, enhancing the detection, monitoring, and prevention of ADEs in ambulatory care.
门诊医疗环境中药物不良事件(ADEs)的研究较少。我们旨在利用电子健康记录(EHRs)评估门诊医疗中ADEs的患病率及特征。
这项横断面研究纳入了2018年10月1日至2019年12月31日在一家学术医疗中心接受门诊诊疗的患者的EHR数据。我们基于一套包含994个与ADE相关的国际疾病分类(ICD - 10)编码制定了分层抽样策略,以识别可能包含ADEs的临床诊疗记录和病历。在每个ICD - 10可能性组内,对临床病历进行随机抽样,并标注当前或可能的ADE - 药物关系及严重程度。计算门诊环境中出现的ADEs的总体估计人群患病率。通过将ICD - 10编码频率与一个大型商业数据库进行比较,评估研究结果的可推广性。
该研究包括来自2882名独特患者的3126份病历(独特的患者诊疗记录)。其中,1383次患者诊疗记录(44.2%)有当前或可能的ADE记录(提及6308次)。在提及的6038例ADEs中,14.1%为过敏反应,1.1%为危及生命的,22.4%为严重的,60.4%为显著的。主要致病药物包括抗感染药(19.3%)、中枢神经系统药物(12.8%)和心血管药物(11.5%)。临床病历中提及的当前ADEs的总体患病率估计为每100次患者诊疗记录中有1.97例(若包括可能的ADEs,则为每100次患者诊疗记录中有2.52例)。
本研究通过利用ICD - 10编码并调查临床病历中记录的ADEs,确定了门诊患者中每次诊疗记录的ADEs总体人群患病率。了解大量门诊文档中的ADE特征可推进药物警戒知识,加强门诊医疗中ADEs的检测、监测和预防。